These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 31013555)

  • 21. Advances in the systemic treatment of pancreatic neuroendocrine tumors.
    Yalcin S
    Cancer Treat Rev; 2011 Apr; 37(2):127-32. PubMed ID: 20705397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances.
    Guilmette JM; Nosé V
    Adv Anat Pathol; 2019 Jan; 26(1):13-30. PubMed ID: 29912000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic therapy for advanced pancreatic neuroendocrine tumors: an update.
    Reidy-Lagunes DL
    J Natl Compr Canc Netw; 2012 Jun; 10(6):777-83. PubMed ID: 22679119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
    Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatic neuroendocrine tumors: Nosography, management and treatment.
    Orditura M; Petrillo A; Ventriglia J; Diana A; Laterza MM; Fabozzi A; Savastano B; Franzese E; Conzo G; Santini L; Ciardiello F; De Vita F
    Int J Surg; 2016 Apr; 28 Suppl 1():S156-62. PubMed ID: 26708853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
    Honma Y; Ikeda M; Hijioka S; Matsumoto S; Ito T; Aoki T; Furuse J
    Invest New Drugs; 2023 Dec; 41(6):777-786. PubMed ID: 37856005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L; Schwarz RE
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world study of everolimus in advanced progressive neuroendocrine tumors.
    Panzuto F; Rinzivillo M; Fazio N; de Braud F; Luppi G; Zatelli MC; Lugli F; Tomassetti P; Riccardi F; Nuzzo C; Brizzi MP; Faggiano A; Zaniboni A; Nobili E; Pastorelli D; Cascinu S; Merlano M; Chiara S; Antonuzzo L; Funaioli C; Spada F; Pusceddu S; Fontana A; Ambrosio MR; Cassano A; Campana D; Cartenì G; Appetecchia M; Berruti A; Colao A; Falconi M; Delle Fave G
    Oncologist; 2014 Sep; 19(9):966-74. PubMed ID: 25117065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A non-functioning pancreatic neuroendocrine tumour: a case report.
    Rosiek V; Kunikowska J; Kos-Kudła B
    Endokrynol Pol; 2012; 63(1):59-64. PubMed ID: 22378100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.
    Smith D; Lepage C; Vicaut E; Dominguez S; Coriat R; Dubreuil O; Lecomte T; Baudin E; Venat Bouvet L; Samalin E; Santos A; Borie O; Bisot-Locard S; Goichot B; Lombard-Bohas C
    Adv Ther; 2022 Jun; 39(6):2731-2748. PubMed ID: 35419649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic neuroendocrine tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy:A retrospective cohort study in the SEER database.
    Zhai H; Li D; Feng Q; Qian X; Li L; Yao J
    Int J Surg; 2019 Jun; 66():103-109. PubMed ID: 30872175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
    Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
    Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.
    Chatani PD; Agarwal SK; Sadowski SM
    Front Endocrinol (Lausanne); 2020; 11():575620. PubMed ID: 33537001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
    Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.
    Gallo M; Malandrino P; Fanciulli G; Rota F; Faggiano A; Colao A;
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1209-1224. PubMed ID: 28405826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor.
    Lin LZ; Li P; Chen HR; Pang LJ
    Future Oncol; 2013 Jun; 9(6):909-13. PubMed ID: 23718311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic neuroendocrine tumors: does chemotherapy work?
    Tejani MA; Saif MW
    JOP; 2014 Mar; 15(2):132-4. PubMed ID: 24618436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.